专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110288118A1 PHARMACEUTICAL COMPOSITION COMPRISING SOLIFENACIN 有权
标题翻译：包含SOLIFENACIN的药物组合物
公开(公告)号：US20110288118A1
公开(公告)日：2011-11-24
申请号：US13110295
申请日：2011-05-18
申请人： Tatsunobu YOSHIOKA , Makoto Murai , Hiroaki Tasaki
发明人： Tatsunobu YOSHIOKA , Makoto Murai , Hiroaki Tasaki
IPC分类号： A61K31/439 , A61P11/00 , A61P11/08 , A61P13/10 , A61P1/00 , A61P1/06 , A61P13/06 , A61P13/00 , A61P11/06
CPC分类号： A61K31/439 , A61K47/32 , A61K47/58 , A61K47/585
摘要： Disclosed is a pharmaceutical composition comprising a complex between solifenacin or a pharmaceutically acceptable salt thereof and an ion exchange resin, and an acrylic based polymer.
摘要翻译：公开了一种药物组合物，其包含索非立新或其药学上可接受的盐与离子交换树脂和丙烯酸类聚合物之间的络合物。

2. 发明授权

US09918970B2 Pharmaceutical composition comprising solifenacin 有权
公开(公告)号：US09918970B2
公开(公告)日：2018-03-20
申请号：US13110295
申请日：2011-05-18
申请人： Tatsunobu Yoshioka , Makoto Murai , Hiroaki Tasaki
发明人： Tatsunobu Yoshioka , Makoto Murai , Hiroaki Tasaki
IPC分类号： A61K31/435 , A61K47/32 , A61K31/439 , A61K47/48
CPC分类号： A61K31/439 , A61K47/32 , A61K47/58 , A61K47/585
摘要： Disclosed is a pharmaceutical composition comprising a complex between solifenacin or a pharmaceutically acceptable salt thereof and an ion exchange resin, and an acrylic based polymer.

3. 发明申请

US20080103124A1 Cefdinir-containing pharmaceutical composition 审中-公开
标题翻译：含头孢非尼的药物组合物
公开(公告)号：US20080103124A1
公开(公告)日：2008-05-01
申请号：US11976351
申请日：2007-10-24
申请人： Tatsunobu Yoshioka , Yoshiyuki Murakami , Noboru Yamashita , Shigemitsu Tomei , Katsumi Saito , Akira Takagi
发明人： Tatsunobu Yoshioka , Yoshiyuki Murakami , Noboru Yamashita , Shigemitsu Tomei , Katsumi Saito , Akira Takagi
IPC分类号： A61K31/00 , A61P43/00
CPC分类号： A61K31/00
摘要： A pharmaceutical composition with an enhanced bioavailability, particularly improved an oral absorption, comprising cefdinir or a pharmaceutically acceptable salt thereof and aminoalkyl methacrylate copolymer E is disclosed.
摘要翻译：公开了具有增强的生物利用度，特别是口服吸收改善的药物组合物，其包含头孢地尼或其药学上可接受的盐和甲基丙烯酸氨基烷基酯共聚物E。

4. 发明申请

US20050163840A1 Drug delivery system for averting pharmacokinetic drug interaction and method thereof 审中-公开
标题翻译：用于避免药代动力学药物相互作用的药物递送系统及其方法
公开(公告)号：US20050163840A1
公开(公告)日：2005-07-28
申请号：US10866524
申请日：2004-06-10
申请人： Toyohiro Sawada , Kazuhiro Sako , Tatsunobu Yoshioka , Shunsuke Watanabe
发明人： Toyohiro Sawada , Kazuhiro Sako , Tatsunobu Yoshioka , Shunsuke Watanabe
IPC分类号： A61K9/00 , A61K9/16 , A61K9/20 , A61K9/22 , A61K9/28 , A61K9/50 , A61K31/341 , A61K31/5517 , A61K31/554
CPC分类号： A61K31/554 , A61K9/1652 , A61K9/2013 , A61K9/2031 , A61K9/2054 , A61K9/2077 , A61K9/2846 , A61K9/2853 , A61K9/2866 , A61K9/2886 , A61K9/5026 , A61K9/5078 , A61K31/341 , A61K31/5517
摘要： The present invention is a system for averting undesirable pharmacokinetic drug interaction between a drug and concomitant drug(s), which consists of controlling the in vivo release time and/or release site of the drug and/or the concomitant drug.
摘要翻译：本发明是用于避免药物和伴随药物之间不期望的药代动力学药物相互作用的系统，其包括控制药物和/或伴随药物的体内释放时间和/或释放部位。

5. 发明授权

US06562375B1 Stable pharmaceutical composition for oral use 有权
标题翻译：稳定的口服药物组合物
公开(公告)号：US06562375B1
公开(公告)日：2003-05-13
申请号：US09629405
申请日：2000-08-01
申请人： Kazuhiro Sako , Toyohiro Sawada , Keiichi Yoshihara , Tatsunobu Yoshioka , Shunsuke Watanabe
发明人： Kazuhiro Sako , Toyohiro Sawada , Keiichi Yoshihara , Tatsunobu Yoshioka , Shunsuke Watanabe
IPC分类号： A61K914
CPC分类号： A61K9/2031 , A61K9/2009
摘要： The present invention is to provide a stable pharmaceutical composition for oral use and preparation thereof in which changes are prevented in drug release at stored even under the exposure to light by adding yellow ferric oxide and/or red ferric oxide in a matrix type sustained-release preparation containing a drug, hydrophilic base, and polyethylene oxide. The present invention is to further provide a method for preventing changes in drug release at stored under the exposure to light in a matrix type sustained-release preparation containing a drug, hydrophilic base, and polyethylene oxide. The quality assurance period of the product can be prolonged and the product value can be improved by the present invention.
摘要翻译：本发明提供一种用于口服使用的稳定药物组合物及其制备方法，其中通过在基质型缓释中加入黄色氧化铁和/或红色氧化铁，甚至在暴露于光下时，在药物释放期间可以防止变化含有药物，亲水性碱和聚环氧乙烷的制剂。本发明进一步提供一种在含有药物，亲水性碱和聚环氧乙烷的基质型缓释制剂中防止在暴露于光下储存的药物释放变化的方法。通过本发明可以延长产品的质量保证期并提高产品价值。

6. 发明申请

US20090239791A1 PHARMACEUTICAL COMPOSITION CONTAINING LIPOPHILIC SUBSTANCE WHICH INHIBITS IL-2 PRODUCTION 审中-公开
标题翻译：含有抑制IL-2生产的脂质物质的药物组合物
公开(公告)号：US20090239791A1
公开(公告)日：2009-09-24
申请号：US12256851
申请日：2008-10-23
申请人： Takayuki Yoshida , Kiyo Nakanishi , Atsushi Maeda , Kazuhiro Sako , Yuki Kasashima , Hiromu Kondo , Tatsunobu Yoshioka , Yuuki Tsutsui
发明人： Takayuki Yoshida , Kiyo Nakanishi , Atsushi Maeda , Kazuhiro Sako , Yuki Kasashima , Hiromu Kondo , Tatsunobu Yoshioka , Yuuki Tsutsui
IPC分类号： A61K38/13 , A61K31/436 , A61K31/343
CPC分类号： A61K9/08 , A61K31/343 , A61K31/365 , A61K31/436 , A61K38/13 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/44
摘要： A pharmaceutical composition comprising a lipophilic substance which inhibits IL-2 production, and a base capable of inhibiting blood exposure of the substance and delivering the substance to lymph following oral administration, is disclosed. The pharmaceutical composition can inhibit blood exposure of the substance to reduce its adverse effects, and can develop desired pharmacological effects.
摘要翻译：公开了一种药物组合物，其包含抑制IL-2产生的亲脂性物质，以及能够抑制物质的血液暴露并将其输送到口服给药后的淋巴液的碱。药物组合物可以抑制物质的血液暴露以减少其不利影响，并且可以产生所需的药理作用。

7. 发明申请

US20080199522A1 TIMED-RELEASE COMPRESSION-COATED SOLID COMPOSITION FOR ORAL ADMINISTRATION 审中-公开
标题翻译：用于口服管理的定时释放压实固体组合物
公开(公告)号：US20080199522A1
公开(公告)日：2008-08-21
申请号：US11841731
申请日：2007-08-20
申请人： Toyohiro Sawada , Kazuhiro Sako , Tatsunobu Yoshioka , Shunsuke Watanabe
发明人： Toyohiro Sawada , Kazuhiro Sako , Tatsunobu Yoshioka , Shunsuke Watanabe
IPC分类号： A61K9/24 , A61K31/55
CPC分类号： A61K9/2853 , A61K9/2893
摘要： The present invention was completed based on these discoveries and relates to in a hydrogel-forming compression-coated solid pharmaceutical preparation comprising a core tablet containing drug and outer layer made from hydrogel-forming polymer substance and hydrophilic base, the improvement, a timed-release compression-coated solid composition for oral administration, said composition comprising (1) drug and freely erodible filler are mixed with the core tablet, (2) the percentage erosion of the core tablet is approximately 40 to approximately 90%, and (3) the outer layer essentially does not contain the same drug as the above-mentioned drug. By releasing a drug after a specific lag time, it becomes possible to effectively deliver a drug to a specific site in the digestive tract. It is therefore useful as presented as a timed-release solid composition for oral administration of a drug that is to be effectively delivered in high concentrations to the afflicted site in the lower digestive tract, a drug that is to be effectively absorbed in the lower digestive tract, a drug that is effective for chronopharmacotherapy, etc.
摘要翻译：本发明是基于这些发现而完成的，涉及一种含水凝胶形成压缩包衣的固体药物制剂，其包含含有药物的核心片剂和由形成水凝胶的聚合物和亲水基质制成的外层，改进，定时释放用于口服给药的压制包衣固体组合物，所述组合物包括（1）药物和自由侵蚀的填料与芯片混合，（2）芯片的侵蚀百分比为约40至约90％，和（3）外层基本上不含有与上述药物相同的药物。通过在特定滞后时间后释放药物，可以有效地将药物递送到消化道中的特定部位。因此，作为口服给药药物的定时释放固体组合物是有效的，其可以高浓度有效地递送到下消化道中的受影响的部位，这是有效地吸收在下消化道中的药物管道，一种对慢性药物疗法有效的药物等

8. 发明申请

US20060292221A1 TIMED-RELEASE COMPRESSION-COATED SOLID COMPOSITION FOR ORAL ADMINISTRATION 审中-公开
标题翻译：用于口服管理的定时释放压实固体组合物
公开(公告)号：US20060292221A1
公开(公告)日：2006-12-28
申请号：US11463570
申请日：2006-08-09
申请人： Toyohiro Sawada , Kazuhiro Sako , Tatsunobu Yoshioka , Shunsuke Watanabe
发明人： Toyohiro Sawada , Kazuhiro Sako , Tatsunobu Yoshioka , Shunsuke Watanabe
IPC分类号： A61K9/22
CPC分类号： A61K9/2853 , A61K9/2031 , A61K9/2893 , A61K31/55
摘要： The present invention was completed based on these discoveries and relates to in a hydrogel-forming compression-coated solid pharmaceutical preparation comprising a core tablet containing drug and outer layer made from hydrogel-forming polymer substance and hydrophilic base, the improvement, a timed-release compression-coated solid composition for oral administration, said composition comprising (1) drug and freely erodible filler are mixed with the core tablet, (2) the percentage erosion of the core tablet is approximately 40 to approximately 90%, and (3) the outer layer essentially does not contain the same drug as the above-mentioned drug. By releasing a drug after a specific lag time, it becomes possible to effectively deliver a drug to a specific site in the digestive tract. It is therefore useful as presented as a timed-release solid composition for oral administration of a drug that is to be effectively delivered in high concentrations to the afflicted site in the lower digestive tract, a drug that is to be effectively absorbed in the lower digestive tract, a drug that is effective for chronopharmacotherapy, etc.
摘要翻译：本发明是基于这些发现而完成的，涉及一种含水凝胶形成压缩包衣的固体药物制剂，其包含含有药物的核心片剂和由形成水凝胶的聚合物和亲水基质制成的外层，改进，定时释放用于口服给药的压制包衣固体组合物，所述组合物包括（1）药物和自由侵蚀的填料与芯片混合，（2）芯片的侵蚀百分比为约40至约90％，和（3）外层基本上不含有与上述药物相同的药物。通过在特定滞后时间后释放药物，可以有效地将药物递送到消化道中的特定部位。因此，作为口服给药药物的定时释放固体组合物是有效的，其可以高浓度有效地递送到下消化道中的受影响的部位，这是有效地吸收在下消化道中的药物管道，一种对慢性药物疗法有效的药物等

9. 发明授权

US06761895B2 Drug delivery system for averting pharmacokinetic drug interaction and method thereof 有权
标题翻译：用于避免药代动力学药物相互作用的药物递送系统及其方法
公开(公告)号：US06761895B2
公开(公告)日：2004-07-13
申请号：US09834414
申请日：2001-04-12
申请人： Toyohiro Sawada , Kazuhiro Sako , Tatsunobu Yoshioka , Shunsuke Watanabe
发明人： Toyohiro Sawada , Kazuhiro Sako , Tatsunobu Yoshioka , Shunsuke Watanabe
IPC分类号： A61K900
CPC分类号： A61K31/554 , A61K9/1652 , A61K9/2013 , A61K9/2031 , A61K9/2054 , A61K9/2077 , A61K9/2846 , A61K9/2853 , A61K9/2866 , A61K9/2886 , A61K9/5026 , A61K9/5078 , A61K31/341 , A61K31/5517
摘要： The present invention is a system for averting undesirable pharmacokinetic drug interaction between a drug and concomitant drug(s), which consists of controlling the in vivo release time and/or release site of the drug and/or the concomitant drug.
摘要翻译：本发明是用于避免药物和伴随药物之间不期望的药代动力学药物相互作用的系统，其包括控制药物和/或伴随药物的体内释放时间和/或释放部位。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式